NYSE:NUVB Nuvation Bio Q3 2024 Earnings Report $3.14 -0.21 (-6.27%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$3.14 0.00 (0.00%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Nuvation Bio EPS ResultsActual EPS-$0.15Consensus EPS -$0.13Beat/MissMissed by -$0.02One Year Ago EPSN/ANuvation Bio Revenue ResultsActual Revenue$0.73 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANuvation Bio Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateTuesday, November 5, 2024Conference Call Time6:00PM ETUpcoming EarningsNuvation Bio's Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Nuvation Bio Earnings HeadlinesNuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from WedbushSeptember 10 at 2:54 AM | americanbankingnews.comNuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on ...September 7, 2025 | finance.yahoo.comREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.September 13 at 2:00 AM | Paradigm Press (Ad)Nuvation Bio’s Phase 3 Study on Taletrectinib: A Potential Game-Changer for NSCLC TreatmentSeptember 7, 2025 | msn.comNuvation Bio announces new data from Phase 2 studies of IBTROZISeptember 7, 2025 | msn.comNuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung CancerSeptember 7, 2025 | businesswire.comSee More Nuvation Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email. Email Address About Nuvation BioNuvation Bio (NYSE:NUVB) is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies. The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors. Nuvation Bio emphasizes a translational science approach, using biomarker strategies and patient-selection criteria to guide trial design and optimize the likelihood of clinical success. Its scientists leverage process chemistry expertise to streamline manufacturing and ensure scalable drug supply. Headquartered in New York, Nuvation Bio conducts global development activities through collaborations with leading academic centers, clinical research organizations, and commercial partners. The company’s leadership team brings extensive experience in drug discovery, translational research, and clinical development from both large pharmaceutical companies and emerging biotechnology firms. Adopting a capital-efficient operating model, Nuvation Bio balances in-house capabilities with strategic outsourcing to manage costs and accelerate timelines. With its focused pipeline and integrated development infrastructure, the company seeks to address critical unmet needs in oncology and advance novel therapies that have the potential to improve patient outcomes.View Nuvation Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
